Eli Lilly

David Hyman

Eli Lilly has appointed David Hyman as chief medical officer. Hyman brings extensive experience across a variety of therapeutic areas and business development. He will continue to serve as chief medical officer at Loxo@Lilly in addition to his new role. Prior to Lilly, Hyman served for over a dec-ade at Memorial Sloan Kettering Cancer Center, most recently as an associate member.

Eli Lilly

Mark Genovese

Eli Lilly has appointed Mark Genovese as senior vice president, immunology development. Geno-vese holds extensive knowledge across a variety of therapeutic areas in several positions of seniority. He most recently served as senior vice president of inflammation development at Gilead Sciences. Prior to this, he also served as a board of director at Lupus Therapeutics, Kyverna Therapeutics and Nēsos.

LifeArc

Stéphane Maikovsky

LifeArc has appointed Stéphane Maikovsky as interim chief executive officer. Maikovsky has obtained in-depth experience in financial, commercial and strategic roles from a variety of senior positions. Alongside his new appointment, he will continue his responsibilities as chief financial officer at LifeArc. Prior to this, he served as emeritus director at the Francis Crick Institute, following his position as chief financial officer.

Neumora Therapeutics

Robert Lenz

Neumora Therapeutics has appointed Robert Lenz as executive vice president, head of research and development. Lenz brings over two decades of experience developing novel drugs in a variety of areas and clinical execution expertise to the role. He previously served in senior positions for over a decade at Amgen, most recently as senior vice president, head of global development.

GSK

Wendy Becker

GSK has appointed Wendy Becker to the board as a non-executive director. Becker brings strong executive management experience to the role and has held a variety of senior positions. She is currently chair of Logitech International, following her role as non-executive director, and is also a board member and chair of the remuneration committee of Oxford Nanopore Technologies.

Mestag Therapeutics

Cassandra
Choe-Juliak

Mestag Therapeutics has appointed Cassandra Choe-Juliak as an expert advisor. Choe-Juliak holds nearly two decades of experience in oncology, medical affairs and clinical drug development. She was previously chief medical officer at Flame Biosciences and has also served as head of clinical develop-ment at Affirmed, following her position as interim chief medical officer. She has also worked at Ipsen, Merck and Celgene.

Mestag Therapeutics

Greg Elson

Mestag Therapeutics has appointed Greg Elson as an expert advisor. Elson brings over two decades of experience in biomanufacturing technologies and product development to his new position. He currently serves as chief technology officer at Alentis Therapeutics. Prior to this, Elson served as an independent consultant at BioPharma Solutions, following his time at Amal Therapeutics, where he was vice president of manufacturing.

Mestag Therapeutics

Samantha Vieira

Mestag Therapeutics has appointed Samantha Vieira as an expert advisor. Vieira has nearly two decades of experience in the biopharmaceutical industry within a wide range of roles. She most recently served as chief operating officer at Anjarium Biosciences. Prior to this, she held the role of executive director, global product development and commercial lead, retinal gene therapy at Biogen.

Eli Lilly

Jennifer Oleksiw

Eli Lilly has appointed Jennifer Oleksiw as group vice president, global chief customer officer. Oleksiw has been with the company for more than two decades and will continue to serve as chief consumer experience officer, vice president and information officer of Lilly business units. Oleksiw originally joined the company to serve as a systems, applications and products analyst.

Pheon Therapeutics

Arvin Yang

Pheon Therapeutics has appointed Arvin Yang as chief medical officer. Yang brings over a decade of experience leading therapeutic oncology products to his new role. He most recently served as chief medical officer at Mersana Therapeutics. Prior to this, he held a variety of leadership positions at Bristol Myers Squibb, including vice president and head, haematology clinical development.

ARTBIO

Nick Pullen

ARTBIO has appointed Nick Pullen as chief scientific officer. Pullen has over two decades of leadership experience in the biopharmaceutical industry in areas including oncology, neuroscience and immunology. Most recently, he served as senior vice president and head of biology at Jnana Therapeutics. Prior to this, he was vice president at Bristol Myers Squibb, and has worked at Roche and Pfizer.

Rezo Therapeutics

Nadir Mahmood

Rezo Therapeutics has appointed Nadir Mahmood as chief executive officer. Mahmood has held a variety of senior positions over the past decade. He most recently served as chief financial and busi-ness officer at Nkarta, following his position as chief business officer and senior vice president of corporate development. Prior to this, he served as senior director of corporate development at Second Genome.

Maxion Therapeutics

Eva-Lotta Allan

Maxion Therapeutics has appointed Eva-Lotta Allan as chair of its board of directors. Allan has extensive experience as board chair and in leadership roles, as well as three decades of corporate, business development and operational expertise. She also currently serves as non-executive chairman for Draupnir Bio. Prior to this, Allan served as a non-executive director at Almirall and Crescendo Biologics.

Spexis

Gonçalo Bernardes

Spexis has appointed Gonçalo Bernardes as acting head of chemical biology. Bernardes has extensive experience in the fields of chemistry and oncology. He currently serves as a full professor in the department of chemistry at the University of Cambridge. Additionally, he has led a satellite lab at the Instituto de Medicina Molecular in Lisbon, Portugal for over a decade.

Acelyrin

Shephard Mpofu

Acelyrin has appointed Shephard Mpofu as senior vice president of development. Mpofu has extensive experience in senior positions and has worked across areas including immunology, rheumatology and dermatology. Mpofu has held several roles at Novartis across nearly two decades, including his most recent position as senior vice president and chief medical officer of the company’s gene therapy franchise.

Bluejay Therapeutics

Christopher Holterhoff

Bluejay Therapeutics has appointed Christopher Holterhoff as senior vice president, head of business development. Holterhoff holds nearly two decades of extensive experience in a variety of areas, including business and corporate development, corporate financing and strategy, equity research and investment banking. He most recently served as vice president of business and corporate development at Lexeo Therapeutics.

Porterhouse Medical

Owen Dawson

Porterhouse Medical has appointed Owen Dawson as associate medical writer. Dawson brings a high level of expertise to his new role, particularly in the treatment of inflammatory diseases. He rejoins Porterhouse after previously completing a 12-week placement at the company as a trainee medical writer, which saw him develop skills in presentation design, editing, reviewing literature and written communication.

Porterhouse Medical

James Carter

Porterhouse Medical has appointed James Carter as senior research executive. James brings over three years of pharmaceutical market experience to his new position and has worked across a broad range of therapeutic areas, including neurological, ophthalmological and rare diseases. He most recently held the position of business analyst at Apex Healthcare Consulting, following his role as a market research executive.

Porterhouse Medical

Sarah Veal

Porterhouse Medical has appointed Sarah Veal as research executive. Veal brings significant scientific expertise to her new role at Porterhouse and has had a variety of experience in healthcare. Most recently, she worked as a serologist as part of a placement at Porton Down, UK Health Security Agency. Additionally, Veal has volunteered at a neurological rehabilitation unit.

IGNIFI

Charlotte Tinmouth

IGNIFI has appointed Charlotte Tinmouth as medical account executive. Smith, who has an educational background in biomedical science, will be supporting the agency’s client services team as part of a year-long placement. She has also previously completed an internship at GSK, which helped her to develop an understanding of research and development processes within the pharmaceutical industry.